Table 1.
Clinical characteristics of patients with metamizole‐induced liver injury
| Group of metamizole‐induced DILI cases | n | Age | Sex | Time of follow‐up | RUCAM score | Re‐challenge | Concurrent causative medication | Presence of ANA | ANA titre | Biochemical pattern (R) | Latency | HE | Steroid treatment | Infectious complications |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| y | Female/male | mo | Hepatocellular/mixed/cholestatic | Weeks | ||||||||||
| All | 23 | 40 (26–79) | 15/23 (65.2%) | 4.5 | 7 (4–11) | 4/23 (17.4%) | 6/23 (26.1%) | 12/23 (52.2%) | 1:160 (1:80–1:5120) | 14/4/5 | 4 (1–135) | 2/23 (8.7%) | 16/23 (69.6%) | 0/23 (0%) |
| Recovery | 21 | 40 (26–79) | 14/2 (54.5) | 4.5 | 7 (4–11) | 4/21 (19.0%) | 4/21 (19%) | 11/21 (52.4%) | 1:160 (1:160–1:5120) | 13/4/4 | 4.5 (1–135) | 0/21 (0%) | 14/21 (66.7%) | 0/21 (0%) |
| ALF and LTX | 2 | 50 (33–67) | 1/2 (50%) | 1 (until LTX‡) | 8 (7–8) | 0/2 (0%) | 2/2 (100%) | 1/2 (50%) | 1:80 | 1/0/1 | 6 (4–8) | 2/2 (100%) | 2/2 (100%) | 0/2 (0%) |
ALF, acute liver failure; ANA, anti‐nuclear antibodies; HE, hepatic encephalopathy; DILI, drug‐induced liver injury; LTX, liver transplantation; RUCAM, Roussel UCLAF Causality Assessment Method (possible 4–5; probable 6–8; highly probable >8).